natgillin/translations-raw huggingface dataset:
Patients with cystic fibrosis have low bodyweight due to problems with digestion of food and high levels of chloride in sweat due to CFTR not working properly. 
Telesna masa bolnikov s cistično fibrozo je zaradi težav pri prebavi hrane nizka, poleg tega pa imajo ti bolniki zaradi nepravilnega delovanja beljakovine CFTR tudi visoke ravni kloridov v znoju.
For the full list of side effects and restrictions with Kalydeco, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Kalydeco glejte navodilo za uporabo.
Two of the studies involved 219 patients with cystic fibrosis who had the G551D mutation. 
Dve študiji sta vključevali 219 bolnikov s cistično fibrozo, ki so imeli mutacijo G551D.
The two medicines are used in patients who have inherited the F508del mutation from both parents and therefore have the mutation in both copies of the CFTR gene. 
Zdravili se uporabljata pri bolnikih, ki so mutacijo F508del podedovali od obeh staršev, zato je ta prisotna v obeh kopijah gena CFTR.
Another study investigated Kalydeco granules in 34 patients aged between 2 and 5 years of age who had cystic fibrosis due to a G551D or S549N mutation. 
V še eni študiji so proučevali zrnca zdravila Kalydeco pri 34 bolnikih, starih od dveh do pet let, ki so imeli cistično fibrozo zaradi oblik mutacij G551D ali S549N.
The second study involved 248 patients with cystic fibrosis who have inherited the F508del mutation from one parent and who also have another CFTR mutation. 
V drugo študijo je bilo vključenih 248 bolnikov s cistično fibrozo, ki so podedovali mutacijo F508del od enega starša in so imeli še eno mutacijo CFTR.
The fourth study involved 69 patients aged 6 years and above with cystic fibrosis who had the R117H mutation. 
Četrta študija je vključevala 69 bolnikov s cistično fibrozo, starejših od šest let, ki so imeli mutacijo R117H.
Kalydeco is also used on its own to treat patients with cystic fibrosis aged 18 years and above who have the R117H mutation in the CFTR gene. 
Zdravilo Kalydeco se samostojno uporablja tudi za zdravljenje bolnikov s cistično fibrozo, starejših od 18 let, ki imajo v genu CFTR mutacijo R117H.
How does Kalydeco work? 
Kako zdravilo Kalydeco deluje?
The doses of Kalydeco may need to be adjusted if the patient is also taking a type of medicine called a ‘moderate or strong CYP3A inhibitor', such as certain antibiotics or medicines for fungal infections. 
„zmeren ali močan zaviralec CYP3A“, kot so nekateri antibiotiki ali zdravila proti glivičnim okužbam.
The third study involved 39 patients over 6 years of age with cystic fibrosis due to several mutations other than G551D. 
V tretjo študijo je bilo vključenih 39 bolnikov, starejših od šest let, s cistično fibrozo zaradi drugih oblik mutacij, ki niso mutacija G551D.
Similar results were seen in patients aged between 6 and 11 years, where Kalydeco treatment led to an improvement of 12.5 percentage points more than with placebo. 
Podobni rezultati so bili opaženi pri bolnikih, starih od šest do 11 let, pri katerih se je zaradi zdravljenja z zdravilom Kalydeco vrednost FEV1 izboljšala za 12,5 odstotne točke več kot pri jemanju placeba.
They are also used in patients who have inherited the F508del mutation from one parent and also have one of the following mutations in CFTR: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, or 3849+10kbC→T. 
Prav tako se uporabljata pri bolnikih, ki so mutacijo F508del podedovali od enega starša in imajo tudi eno od naslednjih mutacij CFTR: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G ali 3849+10kbC→T.
Kalydeco used on its own or together with tezacaftor / ivacaftor has been shown to improve lung function in patients with specific mutations. 
Dokazano je bilo, da samostojna uporaba zdravila Kalydeco ali njegova uporaba v kombinaciji s tezakaftorjem in ivakaftorjem izboljšujeta delovanje pljuč pri bolnikih z določenimi mutacijami.
How is Kalydeco used? 
Kako se zdravilo Kalydeco uporablja?
Patients who took Kalydeco and tezacaftor / ivacaftor had an average increase in FEV1 of 6.5 percentage points compared with an increase of 4.4 percentage points in patients who took Kalydeco alone and a reduction of 0.3 percentage points in patients who took placebo. 
Pri bolnikih, ki so jemali zdravilo Kalydeco v kombinaciji s tezakaftorjem in ivakaftorjem, se je vrednost FEV1 povprečno povečala za 6,5 odstotne točke, medtem ko se je pri bolnikih, ki so jemali samo zdravilo Kalydeco, povečala za 4,4 odstotne točke, pri bolnikih, ki so jemali placebo, pa zmanjšala za 0,3 odstotne točke.
Kalydeco can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Kalydeco je le na recept.
Kalydeco is also used together with another cystic fibrosis medicine containing the active substances tezacaftor and ivacaftor to treat patients with cystic fibrosis aged 12 years and above who have a mutation called F508del in the CFTR gene. 
Zdravilo Kalydeco se uporablja tudi skupaj z drugim zdravilom za zdravljenje cistične fibroze, ki vsebuje učinkovini tezakaftor in ivakaftor, in sicer za zdravljenje bolnikov s cistično fibrozo, starejših od 12 let, ki imajo v genu CFTR mutacijo F508del.
However, when analysing the subset of patients aged 18 years and above alone, an average improvement of around 5.0 percentage points was seen in patients who took Kalydeco compared with patients who took placebo. 
Kljub temu je bilo pri analizi samo podskupine bolnikov, starejših od 18 let, pri bolnikih, ki so jemali zdravilo Kalydeco, opaziti povprečno izboljšanje za približno 5,0 odstotne točke več kot pri tistih, ki so jemali placebo.
F508del mutation from both parents or F508del mutation from one parent and P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G or 3849+10kbC→T mutations 
Mutacija F508del, podedovana od obeh staršev, ali mutacija F508del, podedovana od enega starša, in mutacije P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G ali 3849+10kbC→T
The mutations are: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R (also known as gating mutations). 
Te oblike mutacij so: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N in S549R (znane kot mutacije spreminjanja prehodnosti kanalčkov celične membrane).
Kalydeco, taken with tezacaftor / ivacaftor, was compared with Kalydeco taken alone and with placebo. 
Zdravilo Kalydeco v kombinaciji s tezakaftorjem in ivakaftorjem so primerjali z zdravilom Kalydeco kot samostojnim zdravilom in placebom.
Kalydeco, taken with tezacaftor / ivacaftor, was compared with placebo. 
Zdravilo Kalydeco v kombinaciji s tezakaftorjem in ivakaftorjem so primerjali s placebom.
After 8 weeks of treatment patients who took Kalydeco had an average improvement of 10.7 percentage points more than those who took placebo. 
Po osmih tednih zdravljenja se je vrednost FEV1 pri bolnikih, ki so jemali zdravilo Kalydeco, povprečno izboljšala za 10,7 odstotne točke več kot pri bolnikih, ki so jemali placebo.
Positive results have also been shown with Kalydeco granules in a study involving 19 children aged 1 to 2 years and 11 children aged 6 months to 1 year. 
V študiji, v katero je bilo vključenih 19 otrok, starih od enega do dveh let, in 11 otrok, starih od šest mesecev do enega leta, so bili opaženi pozitivni rezultati pri uporabi zrnc zdravila Kalydeco.
After 24 weeks of treatment, patients aged 12 years and older who took Kalydeco had an average improvement in FEV1 of 10.6 percentage points more than those who took placebo. 
Po 24 tednih zdravljenja se je vrednost FEV1 pri bolnikih, starih 12 let ali več, ki so jemali zdravilo Kalydeco, povprečno izboljšala za 10,6 odstotne točke več kot pri bolnikih, ki so jemali placebo.
No difference was seen between placebo and Kalydeco for children aged 6 years and above. 
Pri otrocih, starejših od šest let, niso opazili razlike med jemanjem placeba in zdravila Kalydeco.
After 24 weeks of treatment, patients who took the medicines had an average increase in FEV1 of 3.4 percentage points compared with a reduction of 0.6 percentage points in patients who took placebo. 
Po 24 tednih zdravljenja se je vrednost FEV1 pri bolnikih, ki so jemali zdravilo Kalydeco v kombinaciji s tezakaftorjem in ivakaftorjem, povprečno povečala za 3,4 odstotne točke, pri bolnikih, ki so jemali placebo, pa se je zmanjšala za 0,6 odstotne točke.
Kalydeco contains the active substance ivacaftor. 
Zdravilo Kalydeco vsebuje učinkovino ivakaftor.
Kalydeco was shown to be effective at improving lung function in 4 main studies involving patients with cystic fibrosis who had various mutations. 
V štirih glavnih študijah pri bolnikih s cistično fibrozo, ki so imeli različne mutacije, je bilo dokazano, da je zdravilo Kalydeco učinkovito pri izboljševanju delovanja pljuč.
Kalydeco taken together with tezacaftor / ivacaftor was shown to be effective at improving lung function in two main studies of patients with cystic fibrosis aged 12 years and above with the the F508del mutation. 
V dveh glavnih študijah pri bolnikih s cistično fibrozo z mutacijo F508del, starejših od 12 let, se je pokazalo, da zdravilo Kalydeco v kombinaciji s tezakaftorjem in ivakaftorjem učinkovito izboljšuje delovanje pljuč.
Invented nameStrength Pharmaceutical Form Route of Administration 
Izmišljeno ime Jakost
Information on how to do this has been included in the product information. 
Informacije o tem, kako to storiti, so vključene v informacije o zdravilu.
Further information on LysaKare can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lysakare. 
Nadaljnje informacije za zdravilo LysaKare so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/lysakare.
The European Medicines Agency therefore decided that LysaKare's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila LysaKare večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of LysaKare? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila LysaKare?
Other information about LysaKare 
Druge informacije o zdravilu LysaKare
As for all medicines, data on the use of LysaKare are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila LysaKare stalno spremljajo.
What is LysaKare and what is it used for? 
Kaj je zdravilo LysaKare in za kaj se uporablja?
As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation. 
Posledično radioaktivno zdravilo zapusti telo z urinom, ledvice pa so izpostavljene manjšemu sevanju.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of LysaKare have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila LysaKare upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is LysaKare authorised in the EU? 
Zakaj je bilo zdravilo LysaKare odobreno v EU?
What benefits of LysaKare have been shown in studies? 
Kakšne koristi je zdravilo LysaKare izkazalo v študijah?
Side effects reported with LysaKare are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu LysaKare, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Because the use of arginine and lysine to protect the kidneys during this type of cancer treatment is well established, the company presented data from the scientific literature. 
Ker je uporaba arginina in lizina za zaščito ledvic med tovrstnim zdravljenjem raka dobro uveljavljena, je družba predstavila podatke iz znanstvene literature.
LysaKare must not be given to patients with high levels of potassium in the blood if this has not been corrected before treatment. 
Zdravilo LysaKare se ne sme dajati bolnikom z visoko vsebnostjo kalija v krvi, če ta pred zdravljenjem ni bila uravnana.
An overview of LysaKare and why it is authorised in the EU 
Pregled zdravila LysaKare in zakaj je odobreno v EU
The most common side effects with LysaKare (which may affect more than 1 in 10 people) are nausea and vomiting. 
Najpogostejša neželena učinka zdravila LysaKare (ki se lahko pojavita pri več kot 1 bolniku od 10) sta navzeja in bruhanje.
For more information about using LysaKare, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila LysaKare glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with LysaKare? 
Kakšna tveganja so povezana z zdravilom LysaKare?
LysaKare is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known. 
Zdravilo LysaKare je povezano tudi s hiperkaliemijo (visokimi ravnmi kalija v krvi), vendar pogostnost tega neželenega učinka ni znana.
Side effects with LysaKare are usually mild or moderate. 
Neželeni učinki zdravila LysaKare so večinoma blagi ali zmerni.
The main risk with LysaKare is a dangerous rise of blood potassium levels but this side effect can be managed if recognised and treated appropriately. 
Glavno tveganje pri zdravilu LysaKare je nevarno povišanje ravni kalija v krvi, vendar se lahko ta neželeni učinek obvladuje, če je ugotovljen in ustrezno zdravljen.
Because LysaKare can cause nausea (feeling sick) and vomiting, patients will be given medicines to prevent nausea and vomiting before receiving LysaKare. 
Zdravilo LysaKare lahko povzroči navzejo (siljenje na bruhanje) in bruhanje, zato bolniki pred prejetjem zdravila LysaKare prejmejo zdravilo za preprečevanje siljenja na bruhanje in bruhanja.
LysaKare is for use in adults and contains the active substances arginine and lysine. 
Zdravilo LysaKare se uporablja pri odraslih in vsebuje učinkovini arginin in lizin.
LysaKare can only be obtained with a prescription and should only be given by a healthcare professional experienced in the use of radioactive medicines. 
Predpisovanje in izdaja zdravila LysaKare je le na recept, zdravljenje pa mora izvajati le zdravnik, ki ima izkušnje z uporabo radoaktivnih zdravil.
In another published study involving 229 patients, measurement of creatinine clearance (an indication of how well the kidneys are working) did not show kidney damage 14 months after patients were treated with arginine and lysine at the same time as lutetium (177Lu) oxodotreotide. 
V drugi objavljeni študiji, ki je vključevala 229 bolnikov, meritev očistka kreatinina (kazalnik, kako dobro ledvice delujejo) ni pokazala poškodb ledvic 14 mesecev po prenehanju zdravljenja bolnikov z argininom in lizinom sočasno z lutecijevim (177Lu) oksodotreotidom.
For the full list of side effects and restrictions with LysaKare, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila LysaKare glejte navodilo za uporabo.
These included data from over 1,200 cancer patients treated with lutetium (177Lu) oxodotreotide, which showed that arginine and lysine were effective at preventing kidney damage. 
Ti so vključevali podatke za več kot 1 200 bolnikov z rakom, zdravljenih z lutecijevim (177Lu) oksodotreotidom, ki so pokazali, da sta arginin in lizin učinkovita pri preprečevanju poškodb ledvic.
Infusion with LysaKare is started 30 minutes before the patient is given lutetium (177Lu) oxodotreotide (also by infusion). 
Infundiranje zdravila LysaKare se začne 30 minut preden se bolniku da lutecijev (177Lu) oksodotreotid (tudi z infuzijo).
LysaKare is a medicine used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. 
LysaKare je zdravilo, ki se uporablja za zaščito ledvic pred poškodbami zaradi sevanja med zdravljenjem raka z radioaktivnim zdravilom, imenovanim lutecijev (177Lu) oksodotreotid.
How is LysaKare used? 
Kako se zdravilo LysaKare uporablja?
The use of arginine and lysine during treatment with lutetium (177Lu) oxodotreotide has been shown to reduce kidney damage and allow patients to be given an effective dose of radioactive treatment for their cancer. 
Dokazano je bilo, da uporaba arginina in lizina med zdravljenjem z lutecijevim (177Lu) oksodotreotidom zmanjšuje poškodbe ledvic in bolnikom omogoča, da dobijo učinkovit odmerek radioaktivnega zdravljenja za zdravljenje raka.
How does LysaKare work? 
Kako zdravilo LysaKare deluje?
Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. 
Sevanje iz lutecijevega (177Lu) oksodotreotida lahko poškoduje ledvične tubule, ko prehaja skoznje.
The active substances in LysaKare, arginine and lysine, interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules. 
Učinkovini v zdravilu LysaKare, arginin in lizin, vplivata na prehod lutecijevega (177Lu) oksodotreotida skozi ledvične tubule.
LysaKare is given by infusion (drip) in to a vein over 4 hours. 
Zdravilo LysaKare se daje kot štiriurna (kapalna) infuzija v veno.
50 mg Powder for solution for infusion 
50 mg prašek za raztopino za infundiranje intravenska uporaba viala (steklo)
≥30% Reduction in Skin Pain b 
≥ 30 % zmanjšanje bolečine na koži b
If you forget to give yourself an injection, you should inject it as soon as you remember. 
Če si pozabite dati injekcijo, si jo morate injicirati, čim se spomnite.
CI 95% for HR 
IZ 95 % za RT
Date of first authorisation: 22 March 2017 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 22. marec 2017
• That Solymbic treatment may increase the potential risks of serious infections, sepsis, 
• Da zdravljenje z zdravilom Solymbic lahko poveča možna tveganja za resne okužbe, sepso,
When you are ready to inject, press the blue start button. 
Ko ste pripravljeni na injiciranje, pritisnite modri sprožilni gumb.
Results from the overall UC-II study population are shown in table 22. 
Rezultate celotne populacije v študiji UC-II prikazuje preglednica 22.
Steroid-free remission for ≥ 90 days 
Remisija brez steroidov za ≥ 90 dni
Your child's doctor will tell you the correct dose to use. 
Otrokov zdravnik vam bo povedal kakšen je ustrezen odmerek, ki ga boste uporabljali.
TNF-antagonists, such as SOLYMBIC affect the immune system and their use may affect the body's defence against infection and cancer. 
TNF-antagonisti, kot je zdravilo SOLYMBIC, prizadanejo imunski sistem in njihova uporaba lahko vpliva na obrambo telesa proti okužbi in raku.
• autoantibodies present in the blood. 
• avtoprotitelesa prisotna v krvi.
* further information is found elsewhere in sections 4.3, 4.4 and 4.8 ** including open-label extension studies 1) including spontaneous reporting data 
* Nadaljnje informacije v zvezi s tem najdete v poglavjih 4.3, 4.4 in 4.8 ** Vključno pri podaljšanih študijah brez placeba Vključno s podatki iz spontanega poročanja
SOLYMBIC in combination with methotrexate, is indicated for: 
Zdravilo SOLYMBIC je v kombinaciji z metotreksatom indicirano za:
Height (cm) 
Višina (cm)
The MAH shall ensure that in each Member State where Solymbic is marketed, all healthcare professionals who are expected to prescribe Solymbic have are provided with the following educational package: 
Imetnik dovoljenja za promet mora zagotoviti, da bodo v vsaki državi članici, ki bodo tržila zdravilo Solymbic, vsi zdravstveni delavci, od katerih se pričakuje, da bodo predpisovali zdravilo Solymbic, prejeli sledeče izobraževalne pakete:
Patients above 4 years of age but with a weight less than 23 kg or between 29 and 46 kg are not possible to dose with this product. 
Bolnikom, starim več kot 4 leta, vendar s telesno maso manj kot 23 kg ali med 29 in 46 kg, tega zdravila ni mogoče odmeriti.
ASDAS Inactive Disease hs-CRP 
ASDAS neaktivna bolezen hs-CRP
Contains latex, read the package leaflet before use. 
Vsebuje lateks, pred uporabo preberite priloženo navodilo.
Significant response was first observed at week 2 and maintained through 24 weeks (table 8). 
Značilen odziv so najprej opazili po 2 tednih in se je ohranil do 24. tedna (preglednica 8).
Rare side effects (may affect up to 1 in 1,000 people): • low blood measurements for white blood cells, red blood cells and platelet count. 
Redki neželeni učinki (lahko prizadenejo do 1 od 1000 bolnikov): • nizke krvne vrednosti za bele krvne celice, rdeče krvne celice in trombocite.
You and your doctor should pay special attention to signs of infection while you are being treated with SOLYMBIC. 
Vi sami in vaš zdravnik morata biti posebej pozorna na znake okužbe, medtem ko ste zdravljeni z zdravilom SOLYMBIC.
If an alternate dose is required, other adalimumab products offering such an option should be used. 
Če je potreben drugačen odmerek, je treba uporabiti druga zdravila z adalimumabom, ki imajo takšno možnost odmerka.
Not known (frequency cannot be estimated from available data): • liver failure. 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): • odpoved jeter.
• Signs or symptoms of the safety concern and when to seek attention from a HCP 
• Znake in simptome varnostnih zadržkov in kdaj poiskati pomoč zdravstvenega delavca.
Children or adolescents weighing 40 kg or more: 
Otroci in mladostniki, ki tehtajo 40 kg ali več:
If you are over 65 years you may be more susceptible to infections while taking SOLYMBIC. 
• Če ste starejši od 65 let, ste morda dovzetnejši za okužbe, če jemljete zdravilo SOLYMBIC.
Week 26 Placebo-controlled 
26. teden Kontrolirana s placebom
Undesirable effects in paediatric patients 
Neželeni učinki pri pediatričnih bolnikih
Your doctor may recommend temporary discontinuation of SOLYMBIC. 
Vaš zdravnik bo morda priporočil začasno prenehanje uporabe zdravila SOLYMBIC.
SOLYMBIC can also be given alone. 
Zdravilo SOLYMBIC se lahko daje tudi samo.
Children or adolescents weighing less than 40 kg: 
Otroci ali mladostniki, ki tehtajo manj kot 40 kg:
a HR of adalimumab versus placebo from proportional hazards regression with treatment as factor. 
RT adalimumaba v primerjavi s placebom iz regresije proporcionalnih tveganj z zdravljenjem kot faktorjem.
Table 15 Efficacy results at 12 weeks, HS studies I and II 
Preglednica 15: Rezultati učinkovitosti v 12. tednu, HS študiji I in II
If you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z vašim zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Other medicines and SOLYMBIC 
Druga zdravila in zdravilo SOLYMBIC
Do not use SOLYMBIC: 
Ne uporabljajte zdravila SOLYMBIC:
Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leucocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). 
Adalimumab modulira tudi biološke odzive, ki jih sproži ali uravnava TNF, vključno s spremembami koncentracije adhezijskih molekul, odgovornih za migracijo levkocitov (ELAM-1, VCAM-1 in ICAM-1 z IK50 0,1-0,2 nM).
Prior to launch of Solymbic in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. 
Še pred začetkom trženja zdravila Solymbic v vsaki državi članici, se mora imetnik dovoljenja za promet z zdravilom uskladiti z nacionalnimi pristojnimi organi o vsebini in obliki izobraževalnih gradiv, vključno s komunikacijskimi mediji, načini distribucije in vseh drugih vidikov gradiv.
b at weeks 24 and 36 after treatment reassignment from weekly adalimumab at week 12 
b v 24. in 36. tednu po spremembi zdravljenja na jemanje adalimumaba vsak teden v 12. tednu